Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661512 | 0.79 | PDK2 (0.40) | OPRM1PDK2OPRD1OPRK1ESR1 | |
| SCHEMBL17591321 | 0.78 | PDK2 (0.42) | PDK2ESR1ESR2CYP2D6TACR1 | |
| SCHEMBL28093369 | 0.77 | ESR2 (0.40) | PDK2ESR2LMNA | |
| SCHEMBL9727613 | 0.77 | OPRM1 (0.41) | OPRM1OPRD1OPRK1ESR1ESR2 | |
| SCHEMBL6401424 | 0.76 | ESR2 (0.41) | OPRM1PDK2ESR1ESR2TACR1 | |
| SCHEMBL6401576 | 0.76 | ESR2 (0.41) | OPRM1PDK2ESR1ESR2TACR1 | |
| SCHEMBL6402105 | 0.76 | ESR2 (0.41) | OPRM1PDK2ESR1ESR2TACR1 | |
| SCHEMBL17591319 | 0.74 | OPRM1 (0.39) | OPRM1OPRD1OPRK1ESR1ESR2 | |
| SCHEMBL16661509 | 0.71 | PDK2 (0.33) | PDK2ALDH1A1LMNACYP3A4 | |
| SCHEMBL6403193 | 0.70 | PDK2 (0.41) | PDK2ESR1ESR2CYP2D6TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718285-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-16 | — | — | EP | claimed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | claimed |
| WO-2013182850-A1 | ISOBENZOFURAN- 5 -YL-OXY- (HETERO) ARYL - IMIDAZOLIDINE - 2, 4 -DIONE DERIVATIVES MODULATORS OF KV3 POTASSIUM CHANNELS FOR THE TREATMENT OF CNS DISORDERS. | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-12-12 | — | — | WO | claimed |
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-11147813-B2 | Modulators of KV3 channels to treat pain | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| EP-2718285-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013182850-A1 | ISOBENZOFURAN- 5 -YL-OXY- (HETERO) ARYL - IMIDAZOLIDINE - 2, 4 -DIONE DERIVATIVES MODULATORS OF KV3 POTASSIUM CHANNELS FOR THE TREATMENT OF CNS DISORDERS. | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-12-12 | — | — | WO | disclosed |
| WO-2012168710-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168710-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | OPRM1 2587/4885PDK2 633/4885OPRD1 1238/4885 |
| US-11147813-B2 | Modulators of KV3 channels to treat pain | KCNN3, KCNA3, KCND3 | OPRM1 173/4885PDK2 2160/4885OPRD1 149/4885 |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | OPRM1 2587/4885PDK2 633/4885OPRD1 1238/4885 |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | OPRM1 2587/4885PDK2 633/4885OPRD1 1238/4885 |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | OPRM1 175/4885PDK2 2110/4885OPRD1 152/4885 |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | OPRM1 1522/4885PDK2 832/4885OPRD1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.